Free tool
FAERS Monitor: Vanflyta
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 216993 or its brand name (Vanflyta, Quizartinib Dihydrochloride). Reports on generic versions are filed under their own applications.
Reports
702
Serious
451
64% of reports
Hospitalization
243
Death reported
107
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- off label use79
- no adverse event71
- death56
- nausea50
- platelet count decreased49
- pyrexia43
- febrile neutropenia39
- fatigue37
- disease progression35
- electrocardiogram qt prolonged35
- infection35
- product dose omission issue32
- pneumonia29
- diarrhoea25
- white blood cell count decreased25
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2012 | 1 |
| 2017 | 2 |
| 2018 | 4 |
| 2019 | 14 |
| 2020 | 7 |
| 2021 | 13 |
| 2022 | 6 |
| 2023 | 34 |
| 2024 | 165 |
| 2025 | 239 |
| 2026 | 217 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,457 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| electrocardiogram qt prolongedSignal | 35 | 29.2 | 21.1 | 925 |
| febrile neutropeniaSignal | 39 | 17.6 | 13.0 | 597 |
| platelet count decreasedSignal | 49 | 13.8 | 10.5 | 571 |
| no adverse eventSignal | 71 | 11.7 | 9.4 | 693 |
| disease progressionSignal | 35 | 8.9 | 6.4 | 238 |
| infectionSignal | 35 | 7.2 | 5.2 | 183 |
| white blood cell count decreasedSignal | 25 | 6.9 | 4.7 | 121 |
| pyrexiaSignal | 43 | 3.7 | 2.8 | 84 |
| product dose omission issueSignal | 32 | 3.3 | 2.3 | 49 |
| off label useSignal | 79 | 2.7 | 2.2 | 87 |
| pneumoniaSignal | 29 | 2.7 | 1.9 | 29 |
| death | 56 | 1.9 | 1.5 | 26 |
| nausea | 50 | 1.9 | 1.4 | 21 |
| fatigue | 37 | 1.4 | 1.0 | 4 |
| diarrhoea | 25 | 1.2 | 0.8 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.